ArticleBMC musculoskeletal disorders2026
Osteoporosis in long-term hospitalized patients with muscular dystrophy: a retrospective cross-sectional study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMuscular dystrophy comprises a group of hereditary muscle disorders characterized by progressive muscle weakness and atrophy, ultimately resulting in the loss of ambulation and wheelchair dependence or confinement to a bed. However, the effects of prolonged hospitalization and immobilization on bone health in patients with advanced muscular dystrophy remain poorly characterized. Therefore, this study aimed to assess osteoporotic characteristics in patients with muscular dystrophy who experienced long-term hospitalization.
methodsPatients with muscular dystrophy undergoing long-term hospitalization were retrospectively reviewed in this cross-sectional study. Bone mineral density (BMD) and bone metabolism markers-including serum albumin, calcium, 25-hydroxy vitamin D [25(OH)D], tartrate-resistant acid phosphatase-5b (TRACP-5b), and bone-specific alkaline phosphatase (BAP)-were evaluated.
resultsA total of 32 patients with muscular dystrophy were included (median age, 50 years). The median duration of hospitalization was 2,287 days (range, 707-16,861 days). Regarding BMD assessment, the median T-scores for the lumbar spine and femoral neck were - 2.2 (interquartile range [IQR], - 4.1 to 0) and - 4.1 (IQR, - 4.6 to - 2.1), respectively. The median serum levels of albumin, calcium, 25(OH)D, TRACP-5b, and BAP were 3.5 g/dL (IQR, 3.2-3.9), 9.0 mg/dL (IQR, 8.8-9.3), 18.8 ng/mL (IQR, 8.7-24.9), 341 mU/dL (IQR, 221-403), and 12.8 U/L (IQR, 10.7-16.0), respectively. Patients with muscular dystrophy exhibited markedly reduced femoral neck BMD and low 25(OH)D levels, whereas lumbar spine BMD was less severely reduced. Levels of serum calcium, TRACP-5b, and BAP were within reference ranges.
conclusionsPatients with muscular dystrophy who required long-term hospitalization and were wheelchair-dependent or bedbound exhibited femoral neck osteoporosis and vitamin D insufficiency/deficiency. These findings may help inform strategies for osteoporotic treatment and nutritional care in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.